Seeking Alpha

Amarin (AMRN +2.3%) gains after Aegis Capital initiated the shares with a Buy this morning and a...

Amarin (AMRN +2.3%) gains after Aegis Capital initiated the shares with a Buy this morning and a 12-month price target of $25. Aegis cites the "compelling efficacy" of the company's lead drug candidate, a heart drug derived from fish oil. Aegis notes the drug's ability to not only lower high levels of triglycerides but also LDL levels gives it an advantage over current omega-3 fatty acid- derived drugs currently on the market.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs